Asset profile

oxaliplatin · RenovoRx, Inc. (RNXT)

Indication: pancreatic cancer
Also known as: intra-arterial oxaliplatin

Company

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arteri…

Start live analysis of RNXT Run 8-agent AI analysis

On the calendar

Apr 2027

Apr 30, 2027

in 181 days

RNXTRenovoRx, Inc.

oxaliplatin: Phase 2 trial NCT07441369 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Apr 2028

Apr 30, 2028

in 547 days

RNXTRenovoRx, Inc.

oxaliplatin: Phase 2 trial NCT07569068 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Oct 2029

Oct 31, 2029

in 1096 days

RNXTRenovoRx, Inc.

oxaliplatin: Phase 1/Phase 2 trial NCT07683949 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

May 28, 2026

12:30 PM

RNXTRenovoRx, Inc.

RenovoRx: FDA grants ODD to oxaliplatin for pancreatic cancer

FDA designationCompany press release

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT01515748	Phase 3	Completed	Jan 21, 2019	530	0 of 1 sites in the United States
NCT07569068	Phase 2	Recruiting	Apr 30, 2028	88	0 of 1 sites in the United States
NCT03607643	Phase 1/2	Unknown	Jun 30, 2020	160	1 of 1 sites in the United States
NCT00069108	Phase 3	Completed	Aug 1, 2006	627	8 of 87 sites in the United States
NCT04701281	Phase 1/2	Terminated	Sep 19, 2022	5	0 of 5 sites in the United States
NCT05236972	Phase 3	Recruiting	Jun 1, 2026	323	0 of 1 sites in the United States
NCT05103020	Phase 2	Unknown	Mar 1, 2023	100	0 of 1 sites in the United States
NCT00004190	Phase 2	Completed	Apr 1, 2003	59	18 of 19 sites in the United States
NCT07441369	Phase 2	Enrolling by invitation	Apr 30, 2027	16	0 of 1 sites in the United States
NCT04337879	Phase 1/2	Unknown	Dec 31, 2020	56	0 of 1 sites in the United States
NCT00476086	Phase 2	Completed	Mar 1, 2012	20	2 of 2 sites in the United States
NCT00305188	Phase 3	Completed	Oct 1, 2009	879	1 of 13 sites in the United States
NCT03221426	Phase 3	Completed	Feb 16, 2024	1007	14 of 171 sites in the United States
NCT05859750	Phase 2	Recruiting	Jun 1, 2025	78	0 of 7 sites in the United States
NCT00005050	Phase 1/2	Completed	Jun 1, 2001		1 of 1 sites in the United States
NCT00262808	Phase 2	Completed	Sep 1, 2006	50	2 of 2 sites in the United States
NCT07683949	Phase 1/2	Enrolling by invitation	Oct 31, 2029	93	0 of 1 sites in the United States
NCT06387810	Phase 2	Unknown	Apr 30, 2026	45	0 of 1 sites in the United States
NCT00552149	Phase 2	Completed	Apr 1, 2012	150	0 of 1 sites in the United States
NCT01442935	Phase 2	Completed	Dec 1, 2015	256	0 of 1 sites in the United States

More from RenovoRx, Inc.

Other drugs and candidates from the same company tracked in this sector.

atezolizumabadjuvant treatment of Stage III mismatch repair deficient (dMMR) colon cancer RenovoCathlocally advanced pancreatic cancer (LAPC)